Premium
Advances in Chimeric Antigen Receptor T‐Cell Therapies for Solid Tumors
Author(s) -
Baybutt Trevor R.,
Flickinger John C.,
Caparosa Ellen M.,
Snook Adam E.
Publication year - 2019
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1280
Subject(s) - chimeric antigen receptor , antigen , immunotherapy , medicine , immunology , cancer research , receptor , immune system
In 2017, the US Food and Drug Administration approved the first two novel cellular immunotherapies using synthetic, engineered receptors known as chimeric antigen receptors ( CARs ), tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta), expressed by patient‐derived T cells for the treatment of hematological malignancies expressing the B‐cell surface antigen CD 19 in both pediatric and adult patients. This approval marked a major milestone in the use of antigen‐directed “living drugs” for the treatment of relapsed or refractory blood cancers, and with these two approvals, there is increased impetus to expand not only the target antigens but also the tumor types that can be targeted. This state‐of‐the‐art review will focus on the challenges, advances, and novel approaches being used to implement CAR T‐cell immunotherapy for the treatment of solid tumors.